| Net income | |
| Depreciation | 222M |
| Amortization of intangible assets | 311M |
| Deferred income taxes | 145M |
| Stock-based compensation | 319M |
| Tax benefits on the exercise of stock options and vesting of restricted stock-based awards | |
| Excess tax benefits on the exercise of stock options and vesting of restricted stock-based awards | |
| Other, net | |
| Decrease in trade receivables, net | 1.99B |
| (Increase) decrease in inventories | -75M |
| Decrease in prepaid expenses and other assets | 435M |
| Decrease in accounts payable and other liabilities | -1.01B |
| Decrease in income taxes payable | |
| Decrease in deferred revenues | 1.76B |
| Net cash provided by operating activities | |
| Purchases of marketable securities and other investments | -5.51B |
| Proceeds from maturities and sales of marketable securities and other investments | 1.75B |
| Acquisitions, net of cash acquired | -1.14B |
| Capital expenditures | |
| Proceeds from sale of property | |
| Net cash used for investing activities | |
| Payments for repurchases of common stock | -2B |
| Proceeds from issuances of common stock | 487M |
| Payment of dividends to stockholders | -618M |
| Proceeds from borrowings, net of issuance costs | |
| Repayments of borrowings | |
| Excess tax benefits on the exercise of stock options and vesting of restricted stock-based awards | |
| Distributions to noncontrolling interests | |
| Net cash (used for) provided by financing activities | |
| Effect of exchange rate changes on cash and cash equivalents | 78M |
| Net increase in cash and cash equivalents | 8.46B |
| Cash and cash equivalents at beginning of period | 20.15B |
| Cash and cash equivalents at end of period | 28.61B |
| Fair value of stock options and restricted stock-based awards assumed in connection with acquisitions | |
| Increase in unsettled repurchases of common stock | |